HRMY | Harmony Biosciences Holdings, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	33.48 - 34.97
52 Week Range	28.14 - 41.61
Beta	0.76
Implied Volatility	88.99%
IV Rank	84.41%
Day's Volume	1,977,666
Average Volume	750,725
Shares Outstanding	57,031,300
Market Cap	1,955,032,964
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-08-19

Valuation
Profitability
Growth
Health
P/E Ratio	16.25
Forward P/E Ratio	N/A
EPS	2.11
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	246
Country	USA
Website	HRMY

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

HRMY's peers: FENC, FOLD, GNFT, KROS, JANX, EWTX, PLRX, SNDX, RVMD, VRDN, INZY, VTYX, NUVL, CERE, TVTX, GPCR, REPL, NVCT, LYRA, KRON, GOSS, IDYA, PTGX, VRNA, IMTX, INCY, INSM, INVA, MRVI, PRTG

*Chart delayed

Analyzing fundamentals for HRMY we got that it has strong fundamentals where Valuation is considered to be slightly undervalued, Profitability is very wealthy, Growth is exceptionally good and Health is strong. For more detailed analysis please see HRMY Fundamentals page.

Watching at HRMY technicals we can see that long-term trend is bullish, while middle-term trend is bearish, but short-term trend is bullish. More technicals details can be found on HRMY Technicals page.